Shortness of breath is one of the hardest symptoms to sort out at the bedside. Heart, lungs, or both? GE HealthCare is betting that AI built into a pocket-sized ultrasound can help clinicians answer that faster, and it has just added two tools to try to do it.
On November 3, 2026, the company announced Lung Guidance and AutoAS for its Vscan Air handheld system. Both are available only on the Vscan Air SL model. They join Caption AI, which guides cardiac scans, and Caption Interpretation Auto EF, which supports ejection fraction assessment.
What Lung Guidance does
Lung ultrasound is useful, but image quality depends heavily on the operator. Lung Guidance addresses that with real-time coaching. It directs users to the right anatomical landmarks in each zone of the standard 8-zone protocol, detecting structures such as the pleural line, A-lines, rib shadows, the diaphragm and the abdomen.
When landmark and image-quality criteria are met, AutoCapture records a clip automatically. If those conditions are not reached, a Save Best Clip feature keeps the best image from each view. The tool also detects and scores B-lines and generates a report to organize findings.
In validation testing, non-expert users acquired diagnostic-quality exams 95.2 percent of the time, compared with 96.8 percent for experts. GE describes this as a descriptive assessment, so it is not a head-to-head trial with formal statistical comparison. Still, a gap of 1.6 points is small.
What AutoAS does
AutoAS looks for moderate-to-severe aortic stenosis. It analyzes standard 2D cardiac images from at least two compatible views: parasternal long-axis, parasternal short-axis at the aortic valve, or apical five-chamber. It then gives an estimate of whether findings suggest moderate-to-severe AS, along with a confidence score.
GE says the algorithm was trained and validated against a reference panel of expert cardiologists, and that it can reduce the variability of missed AS compared with visual interpretation alone. The company has not published specific performance figures in this announcement. The tool is labeled a diagnostic aid, not a standalone diagnosis, and final decisions stay with the clinician and formal echocardiography.
Why it matters
Aortic stenosis is often underrecognized, and access to formal echo can lag, particularly outside large centers. A screening-style flag at the first encounter could prompt earlier referral. That is the realistic ambition here: not replacing the echo lab, but shortening the wait before someone gets there.
The broader trend is clear. Point-of-care ultrasound is spreading to more users, including those with limited training, and AI guidance is the main way vendors are trying to keep quality acceptable. Clinicians evaluating these tools should ask for independent data, especially on how AutoAS performs across patient populations and in the hands of novices.
Availability
Both tools are FDA 510(k) cleared and CE marked. They are sold through Vscan Air Innovation Packages in the United States and select countries. Existing customers with a valid Innovation Package subscription or license should receive the updates by the end of November 2026. Offerings vary by location and system model.